News | June 06, 2022
Proxygen and Merck collaborates to develop molecular glue degraders
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
Innate to receive $5M milestone payment from AstraZeneca
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Includes thermostabilized Ebola vaccines
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
Subscribe To Our Newsletter & Stay Updated
